27S Stock Overview
Through its subsidiaries, engages in the operation of food and drug stores in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Albertsons Companies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.30 |
| 52 Week High | US$22.65 |
| 52 Week Low | US$17.40 |
| Beta | 0.33 |
| 11 Month Change | 1.11% |
| 3 Month Change | -1.61% |
| 1 Year Change | -10.73% |
| 33 Year Change | -32.22% |
| 5 Year Change | n/a |
| Change since IPO | 48.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 27S | DE Consumer Retailing | DE Market | |
|---|---|---|---|
| 7D | 1.1% | -5.3% | 1.4% |
| 1Y | -10.7% | -43.7% | 5.0% |
Return vs Industry: 27S exceeded the German Consumer Retailing industry which returned -43.7% over the past year.
Return vs Market: 27S underperformed the German Market which returned 5% over the past year.
Price Volatility
| 27S volatility | |
|---|---|
| 27S Average Weekly Movement | 2.5% |
| Consumer Retailing Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 27S has not had significant price volatility in the past 3 months.
Volatility Over Time: 27S's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1860 | 196,650 | Vivek Sankaran | www.albertsonscompanies.com |
Albertsons Companies, Inc., through its subsidiaries, engages in the operation of food and drug stores in the United States. The company’s food and drug retail stores offer grocery products, general merchandise, health and beauty care products, pharmacy, fuel, and other items and services. It also manufactures and processes food products for sale in stores.
Albertsons Companies, Inc. Fundamentals Summary
| 27S fundamental statistics | |
|---|---|
| Market cap | €10.56b |
| Earnings (TTM) | €1.01b |
| Revenue (TTM) | €71.59b |
10.5x
P/E Ratio0.1x
P/S RatioIs 27S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 27S income statement (TTM) | |
|---|---|
| Revenue | US$79.45b |
| Cost of Revenue | US$56.88b |
| Gross Profit | US$22.58b |
| Other Expenses | US$21.46b |
| Earnings | US$1.12b |
Last Reported Earnings
Jun 15, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.93 |
| Gross Margin | 28.42% |
| Net Profit Margin | 1.41% |
| Debt/Equity Ratio | 254.5% |
How did 27S perform over the long term?
See historical performance and comparison